168 related articles for article (PubMed ID: 36246597)
1. Analysis and identification of the necroptosis landscape on therapy and prognosis in bladder cancer.
Zhao Z; Jiang N; Zhang Y; Bai Y; Liu T; Li T; Guo H; Yang R
Front Genet; 2022; 13():919829. PubMed ID: 36246597
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
3. Identification and Quantification of Iron Metabolism Landscape on Therapy and Prognosis in Bladder Cancer.
Song X; Xin S; Zhang Y; Mao J; Duan C; Cui K; Chen L; Li F; Liu Z; Wang T; Liu J; Liu X; Song W
Front Cell Dev Biol; 2022; 10():810272. PubMed ID: 35265613
[TBL] [Abstract][Full Text] [Related]
4. Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma.
Zhang F; Liang J; Feng D; Liu S; Wu J; Tang Y; Liu Z; Lu Y; Wang X; Wei X
Front Cell Dev Biol; 2022; 10():814735. PubMed ID: 35281080
[No Abstract] [Full Text] [Related]
5. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
7. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
8. Prognosis Risk Model Based on Necroptosis-Related Signature for Bladder Cancer.
Chen Z; Cao R; Wang R; Wang Y; Shang D; Tian Y
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36421795
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of necroptosis-related long noncoding RNA signatures in muscle-invasive bladder cancer.
Jiang K; Wu L; Yin X; Tang Q; Yin J; Zhou Z; Yu H; Yan S
Front Genet; 2022; 13():1036098. PubMed ID: 36531246
[No Abstract] [Full Text] [Related]
10. Identification and Quantification of Necroptosis Landscape on Therapy and Prognosis in Kidney Renal Clear Cell Carcinoma.
Xin S; Mao J; Duan C; Wang J; Lu Y; Yang J; Hu J; Liu X; Guan W; Wang T; Wang S; Liu J; Song W; Song X
Front Genet; 2022; 13():832046. PubMed ID: 35237304
[TBL] [Abstract][Full Text] [Related]
11. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B
PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921
[TBL] [Abstract][Full Text] [Related]
13. Identification of necroptosis-related gene signature and characterization of tumour microenvironment infiltration in non-small-cell lung cancer.
Dai J; Fu Y
J Cell Mol Med; 2022 Sep; 26(17):4698-4709. PubMed ID: 35871768
[TBL] [Abstract][Full Text] [Related]
14. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
Gao X; Cai J
Front Genet; 2022; 13():865204. PubMed ID: 35571063
[No Abstract] [Full Text] [Related]
16. Revealing prognostic and tumor microenvironment characteristics of cuproptosis in bladder cancer by genomic analysis.
Zhang S; Yu S; Duan H; Xia W; Wang C; Shen H
Front Genet; 2022; 13():997573. PubMed ID: 36263417
[No Abstract] [Full Text] [Related]
17. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
Zhang H; Song J; Dong J; Liu Z; Lin L; Wang B; Ma Q; Ma L
Front Genet; 2021; 12():551605. PubMed ID: 33732281
[No Abstract] [Full Text] [Related]
18. Integrated bioinformatics analysis identifies a Ferroptosis-related gene signature as prognosis model and potential therapeutic target of bladder cancer.
Liu Z; Du D; Zhang S
Toxicol Res (Camb); 2024 Feb; 13(1):tfae010. PubMed ID: 38292893
[TBL] [Abstract][Full Text] [Related]
19. Development of a necroptosis-related gene signature and the immune landscape in ovarian cancer.
Nie S; Ni N; Chen N; Gong M; Feng E; Liu J; Liu Q
J Ovarian Res; 2023 Apr; 16(1):82. PubMed ID: 37095524
[TBL] [Abstract][Full Text] [Related]
20. Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis.
Deng Y; Hong X; Yu C; Li H; Wang Q; Zhang Y; Wang T; Wang X
Oncol Lett; 2021 May; 21(5):344. PubMed ID: 33747201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
